These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 23664070)

  • 1. [Thrombotic thrombocytopenic purpura associated with interferon therapy in a HIV and HCV co-infected woman].
    Michaux C; Randrianasolo D; Vandenhende MA; Hessamfar M; Morlat P; Bonnet F
    Rev Med Interne; 2013 Dec; 34(12):773-5. PubMed ID: 23664070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Thrombotic thrombocytopenic purpura mediated by an ADAMTS13-inhibitor related to a treatment with pegylated-interferon alpha-2a and ribavirine in a patient with chronic hepatitis C].
    Lambot F; Hanson B; Sztern B
    Presse Med; 2010 Nov; 39(11):1207-10. PubMed ID: 20609558
    [No Abstract]   [Full Text] [Related]  

  • 3. HIV & hepatitis C: treatment.
    WORLD; 2002 May; (133):4-5. PubMed ID: 12064298
    [No Abstract]   [Full Text] [Related]  

  • 4. Cytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: safety analysis of the OPERA study.
    Pontali E; Angeli E; Cattelan AM; Maida I; Nasta P; Verucchi G; Caputo A; Iannacone C; Puoti M
    Antivir Ther; 2015; 20(1):39-48. PubMed ID: 24831457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study.
    Poizot-Martin I; Bellissant E; Garraffo R; Colson P; Piroth L; Solas C; Renault A; Bourlière M; Halfon P; Ghosn J; Alric L; Naqvi A; Carrieri P; Molina JM;
    HIV Clin Trials; 2016 Mar; 17(2):63-71. PubMed ID: 27077673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-infections. German doctors treat hepatitis C early, with some success.
    TreatmentUpdate; 2006; 18(5):3-4. PubMed ID: 17209229
    [No Abstract]   [Full Text] [Related]  

  • 7. A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy.
    Murata M; Furusyo N; Ogawa E; Mitsumoto F; Hiramine S; Ikezaki H; Takayama K; Shimizu M; Toyoda K; Kainuma M; Hayashi J
    J Infect Chemother; 2014 May; 20(5):320-4. PubMed ID: 24477330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Thrombotic thrombocytopenic purpura during treatment with interpheron].
    Serrano A; Xicoy B; Grifols JR; Ribera JM
    Med Clin (Barc); 2007 Feb; 128(7):276-7. PubMed ID: 17335744
    [No Abstract]   [Full Text] [Related]  

  • 9. Rhabdomyolysis associated with the co-administration of daptomycin and pegylated interferon α-2b and ribavirin in a patient with hepatitis C.
    Colomba C; Rubino R; Siracusa L; Mazzola G; Titone L
    J Antimicrob Chemother; 2012 Jan; 67(1):249-50. PubMed ID: 21965434
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of individualization of hepatitis C virus (HCV) therapy duration in HIV/HCV-coinfected individuals.
    Hopkins S; Lambourne J; Farrell G; McCullagh L; Hennessy M; Clarke S; Mulcahy F; Bergin C
    HIV Med; 2006 May; 7(4):248-54. PubMed ID: 16630037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crohn's disease onset in an HIV/hepatitis C virus co-infected woman taking pegylated interferon alpha-2b plus ribavirin.
    Bongiovanni M; Ranieri R; Ferrero S; Casanova F; Monforte Ad
    AIDS; 2006 Oct; 20(15):1989-90. PubMed ID: 16988527
    [No Abstract]   [Full Text] [Related]  

  • 12. Safe coadministration of raltegravir-based HAART in HIV-infected patients with HCV-cirrhosis receiving triple therapy with telaprevir or boceprevir.
    Moreno A; Quereda C; Montes M; Pérez-Elías MJ; Casado JL; Rodríguez-Sagrado MA; Mateos ML; Dronda F; Bárcena R; Del Campo S; Moreno S
    J Acquir Immune Defic Syndr; 2012 Nov; 61(3):e47-9. PubMed ID: 23095936
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful treatment with telaprevir of post-transplant fibrosing cholestatic hepatitis C in an HIV co-infected patient.
    Marciano S; Galdame OA; Barcan LA; Gadano AC
    Acta Gastroenterol Latinoam; 2015 Mar; 45(1):76-9. PubMed ID: 26076519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis.
    Shire NJ; Welge JA; Sherman KE
    J Viral Hepat; 2007 Apr; 14(4):239-48. PubMed ID: 17381715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short communication. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy.
    Fuster D; Huertas JA; Gómez G; Solà R; González García J; Vilaró J; Pedrol E; Force L; Tor J; Sirera G; Videla S; Planas R; Clotet B; Tural C;
    Antivir Ther; 2005; 10(7):841-7. PubMed ID: 16312180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients.
    Osinusi A; Bon D; Nelson A; Lee YJ; Poonia S; Shivakumar B; Cai SY; Wood B; Haagmans B; Lempicki R; Herrmann E; Sneller M; Polis M; Masur H; Kottilil S
    J Med Virol; 2014 Feb; 86(2):177-85. PubMed ID: 24166150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of hepatitis C virus infection in patients with concurrent human immunodeficiency virus infection].
    Peters L; Lindhardt BØ
    Ugeskr Laeger; 2006 Oct; 168(42):3604-8. PubMed ID: 17069721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of an induction period of pegylated interferon-α2a and ribavirin on early virological response in HIV-HCV-coinfected patients: results from the CORAL-2 study.
    Tural C; Solà R; Alvarez NP; Moltó J; Sánchez M; Zamora AM; Ornelas A; Laguno M; González J; von Wichmann MÁ; Téllez MJ; Paredes R; Clotet B;
    Antivir Ther; 2011; 16(6):833-41. PubMed ID: 21900715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OPERA: use of pegylated interferon plus ribavirin for treating HCV-HIV coinfection in interferon-naive patients.
    Carosi G; Bruno R; Cariti G; Nasta P; Gulminetti R; Galli M; Angarano G; Verucchi G; Pontali E; Capetti A; Raise E; Ravasio V; Maida I; Iannacone C; Caputo A; Puoti M
    Antivir Ther; 2014; 19(8):735-45. PubMed ID: 24583976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Hepatitis C (HCV) treatment is not a "one size fits all".
    Bukeirat FA; Bukeirat MM
    W V Med J; 2012; 108(2):20, 22-4. PubMed ID: 22655431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.